Central Valley Advisors LLC Takes Position in Pfizer Inc. (NYSE:PFE)

Central Valley Advisors LLC bought a new stake in Pfizer Inc. (NYSE:PFE) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 7,353 shares of the biopharmaceutical company’s stock, valued at approximately $212,000.

Several other large investors have also modified their holdings of PFE. Clifford Swan Investment Counsel LLC boosted its stake in Pfizer by 4.7% during the 4th quarter. Clifford Swan Investment Counsel LLC now owns 417,070 shares of the biopharmaceutical company’s stock worth $12,007,000 after purchasing an additional 18,611 shares during the period. Adage Capital Partners GP L.L.C. grew its position in shares of Pfizer by 40.5% in the third quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock valued at $157,215,000 after purchasing an additional 1,365,295 shares during the last quarter. LifePlan Financial LLC purchased a new position in shares of Pfizer during the 4th quarter worth approximately $255,000. KLCM Advisors Inc. raised its position in shares of Pfizer by 75.0% during the 4th quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company’s stock worth $5,004,000 after purchasing an additional 74,487 shares during the last quarter. Finally, Farmers Trust Co. lifted its stake in Pfizer by 2.0% in the 4th quarter. Farmers Trust Co. now owns 225,881 shares of the biopharmaceutical company’s stock valued at $6,503,000 after buying an additional 4,410 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Up 2.2 %

Shares of PFE stock traded up $0.64 during mid-day trading on Wednesday, reaching $29.20. The company’s stock had a trading volume of 29,229,239 shares, compared to its average volume of 42,373,320. The company’s 50 day simple moving average is $27.22 and its 200-day simple moving average is $27.96. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $40.37. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $165.46 billion, a PE ratio of -485.42, a price-to-earnings-growth ratio of 1.20 and a beta of 0.63.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. The firm had revenue of $14.88 billion for the quarter, compared to analyst estimates of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The firm’s revenue was down 19.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.23 EPS. On average, research analysts predict that Pfizer Inc. will post 2.39 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be given a dividend of $0.42 per share. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 annualized dividend and a dividend yield of 5.75%. Pfizer’s payout ratio is -2,799.53%.

Wall Street Analyst Weigh In

A number of research firms recently commented on PFE. Argus cut Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Morgan Stanley upped their price objective on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday, May 2nd. Guggenheim assumed coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 target price on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Monday, April 15th. Finally, BMO Capital Markets restated an “outperform” rating and set a $36.00 target price (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Ten equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $35.86.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.